Literature DB >> 17041852

Identification of CT521 as a frequent target of Th1 cells in patients with urogenital Chlamydia trachomatis infection.

Anja Weinreich Olsen1, Frank Follmann, Klaus Jensen, Peter Højrup, Robert Leah, Hanne Sørensen, Steen Hoffmann, Peter Andersen, Michael Theisen.   

Abstract

BACKGROUND: The human immune response to a Chlamydia trachomatis serovar D lysate was investigated in patients with urogenital C. trachomatis infection, to identify novel T cell targets.
METHODS: A C. trachomatis lysate was fractionated on the basis of molecular mass, and each fraction was used to stimulate peripheral-blood mononuclear cells from patients with C. trachomatis infection. In frequently recognized fractions, proteins were identified by mass spectrometry, recombinantly expressed, and tested for T cell recognition.
RESULTS: T cell recognition of the fractions was highly heterogeneous in patients with C. trachomatis infection (n=16). Four patients exhibited responses that were strongly targeted to antigens of 16-20-kDa molecular mass. Three proteins were identified in this fraction: CT043, CT511, and CT521. The T cell response to the individual recombinant proteins were investigated, and CT521 was found to induce the highest level of interferon (IFN)- gamma. The recognition of CT521 was investigated in a larger study population (n=41), and a positive IFN-gamma response was measured in 83% of the patients. Several T cell epitopes were identified in CT521; in particular, peptide 5 in the central part of the protein was frequently recognized by T cells (63%).
CONCLUSION: We have identified a novel C. trachomatis antigen, CT521, that is frequently recognized in patients with urogenital C. trachomatis infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17041852     DOI: 10.1086/508203

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans.

Authors:  Eva Meoni; Elisa Faenzi; Elisabetta Frigimelica; Luisanna Zedda; David Skibinski; Serena Giovinazzi; Alessandra Bonci; Roberto Petracca; Erika Bartolini; Giuliano Galli; Mauro Agnusdei; Filomena Nardelli; Francesca Buricchi; Nathalie Norais; Ilaria Ferlenghi; Manuela Donati; Roberto Cevenini; Oretta Finco; Guido Grandi; Renata Grifantini
Journal:  Infect Immun       Date:  2009-07-13       Impact factor: 3.441

2.  Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model.

Authors:  Anja Weinreich Olsen; Michael Theisen; Dennis Christensen; Frank Follmann; Peter Andersen
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

3.  Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response Profile.

Authors:  Michele D Picard; Jean-Luc Bodmer; Todd M Gierahn; Alexander Lee; Jessica Price; Kenya Cohane; Veronica Clemens; Victoria L DeVault; Galina Gurok; Robert Kohberger; Darren E Higgins; George R Siber; Jessica Baker Flechtner; William M Geisler
Journal:  Clin Vaccine Immunol       Date:  2015-10-07

4.  Systemic effector and regulatory immune responses to chlamydial antigens in trachomatous trichiasis.

Authors:  Alevtina Gall; Amir Horowitz; Hassan Joof; Angels Natividad; Kevin Tetteh; Eleanor Riley; Robin L Bailey; David C W Mabey; Martin J Holland
Journal:  Front Microbiol       Date:  2011-02-10       Impact factor: 5.640

Review 5.  Chlamydia trachomatis vaccine research through the years.

Authors:  Katelijn Schautteet; Evelien De Clercq; Daisy Vanrompay
Journal:  Infect Dis Obstet Gynecol       Date:  2011-06-26

Review 6.  Chlamydia trachomatis Genital Infections.

Authors:  Catherine M O'Connell; Morgan E Ferone
Journal:  Microb Cell       Date:  2016-09-05

7.  A flow cytometry-based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis.

Authors:  Marco Grasse; Ida Rosenkrands; Anja Olsen; Frank Follmann; Jes Dietrich
Journal:  Cytometry A       Date:  2018-03-07       Impact factor: 4.355

8.  Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.

Authors:  Else Marie Agger; Ida Rosenkrands; Jon Hansen; Karima Brahimi; Brian S Vandahl; Claus Aagaard; Kerstin Werninghaus; Carsten Kirschning; Roland Lang; Dennis Christensen; Michael Theisen; Frank Follmann; Peter Andersen
Journal:  PLoS One       Date:  2008-09-08       Impact factor: 3.240

9.  Genital tract lesions in sexually mature Göttingen minipigs during the initial stages of experimental vaginal infection with Chlamydia trachomatis serovar D.

Authors:  Karin Erneholm; Emma Lorenzen; Sarah Bøje; Anja Weinreich Olsen; Peter Andersen; Joseph P Cassidy; Frank Follmann; Henrik E Jensen; Jørgen S Agerholm
Journal:  BMC Vet Res       Date:  2016-09-10       Impact factor: 2.741

10.  A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigs.

Authors:  Sarah Bøje; Anja Weinreich Olsen; Karin Erneholm; Jørgen Steen Agerholm; Gregers Jungersen; Peter Andersen; Frank Follmann
Journal:  Immunol Cell Biol       Date:  2015-08-13       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.